Pfizer begins testing its COVID-19 pill for children aged between 6-17
Category: #healthcare  By Akshay Kedari  Date: 2022-03-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pfizer begins testing its COVID-19 pill for children aged between 6-17

Pfizer Inc. recently announced that it has started a middle-to-late-stage study of its COVID-19 pill for non-hospitalized kids aged between 6-17 years, who are likely to be at high risk of developing severe disease.

Pfizer's antiviral pill, Paxlovid has an emergency use authorization in the United States for kids aged 12 years or older and among high-risk adults. However, there are no oral treatments for COVID-19 authorized in the U.S. for younger children as of now.

The drug manufacturer’s study will involve 140 children across 2 groups of 6-17 year-olds, with one group consisting of children weighing 40 kgs and above, and the other group including children weighing between 20-40 kgs.

The Chief Scientific Officer at Pfizer, Mikael Dolsten was quoted saying that over 11 million children below the age group of 18 have tested positive for Covid-19 in the U.S. since the beginning of the pandemic. This figure represents nearly 18% of the total reported cases and has led to over 100,000 hospital admissions.

Dolsten added that there is a massive unmet need for outpatient methods of treatment for children and adolescents to prevent the onset of severe illnesses caused by infection from COVID -19, which can lead to hospitalization and even death.

Meanwhile, Pfizer is currently working to formulate an age-adjusted format of the drug for patients below 6 years and will begin testing on 3 different groups of kids under 6 years, once the modified formulation is ready for trial.

It is worth noting that results from a mid-to-late-stage trial conducted in November last year showed that Paxlovid was almost 90% effective in preventing deaths and hospitalizations as compared to placebo drugs in adults at high risk of severe illness.

Source Credits –

https://www.businesstimes.com.sg/consumer/pfizer-begins-covid-pill-study-in-high-risk-children-aged-6-17

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Brookfield to invest $1 bn in Greenko to boost decarbonization efforts
Brookfield to invest $1 bn in Greenko to boost decarbonization efforts
By Akshay Kedari

Brookfield Asset Management is in discussions with Greenko to invest around $1 billion in ...

Lepaya acquires vCOACH to expand operations across Europe
Lepaya acquires vCOACH to expand operations across Europe
By Akshay Kedari

Lepaya, the Amsterdam-based power skills training provider, has reportedly acquired German digital c...

SmileDirectClub launches new retainer manufacturing technology
SmileDirectClub launches new retainer manufacturing technology
By Akshay Kedari

Next-generation dental care firm, SmileDirectClub, Inc., with its novel MedTech platform for teeth s...